首页> 美国卫生研究院文献>Future Medicinal Chemistry >Developing RNA aptamers for potential treatment of neurological diseases
【2h】

Developing RNA aptamers for potential treatment of neurological diseases

机译:开发用于神经疾病潜在治疗的RNA适体

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AMPA receptor antagonists are drug candidates for potential treatment of a number of CNS diseases that involve excessive receptor activation. To date, small-molecule compounds are the dominating drug candidates in the field. However, lower potency, cross activity and poor water solubility are generally associated with these compounds. Here we show the potential of RNA-based antagonists or RNA aptamers as drug candidates and some strategies to discover these aptamers from a random sequence library (∼10 sequences). As an alternative to small molecule compounds, our aptamers exhibit higher potency and selectivity toward AMPA receptors. Because aptamers are RNA molecules, they are naturally water soluble. We also discuss the major challenges of translating RNA aptamers as lead molecules into drugs/treatment options.
机译:AMPA受体拮抗剂是潜在治疗许多涉及受体过度活化的中枢神经系统疾病的候选药物。迄今为止,小分子化合物是该领域的主要候选药物。然而,这些化合物通常具有较低的效力,交叉活性和差的水溶性。在这里,我们展示了基于RNA的拮抗剂或RNA适体作为候选药物的潜力,以及从随机序列库(约10个序列)中发现这些适体的一些策略。作为小分子化合物的替代品,我们的适体对AMPA受体表现出更高的效能和选择性。因为适体是RNA分子,所以它们自然是水溶性的。我们还讨论了将RNA适体作为先导分子转化为药物/治疗选择的主要挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号